Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Unum Therapeutics Inc.
DescriptionAntibody-targeted tumor cell killing (ATTCK) therapy using a combination of autologous T-lymphocytes engineered to express a CD16-41BB-CD3zeta chimeric receptor administered with rituximab, a mAb targeting CD20
Molecular Target CD20
Mechanism of ActionCell therapy; Antibody
Therapeutic ModalityCell therapy: Non-stem cell

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today